A groundbreaking clinical trial is exploring psychedelics as a potential treatment for postpartum depression in the United States, with early results showing remarkable promise. The study involved 84 women nationwide and aims to develop the first federally approved psychedelic therapy for this condition.
Participants who received the full dose of RE104, a compound similar to psilocybin, experienced a “clinically meaningful” reduction in depression symptoms within just one week, according to the company leading the trial, Reunion.
Researchers assessed participants using a clinical depression rating scale that measures symptoms including persistent sadness, sleep disruption, and changes in appetite.
Remarkably, 71% of women who received the full dose were classified as in remission within a week—a benefit that persisted for at least one month following treatment.
During the trial, participants were not able to breastfeed. However, preliminary findings from a separate lactation study conducted by the company indicate that RE104 traces in breast milk are extremely low—“an order of magnitude below the level that might potentially cause risk to the infant,” Reunion reported.
This study represents a significant step forward in the search for innovative therapies for postpartum depression, a condition affecting thousands of new mothers each year.
